Form 6-K ASTRAZENECA PLC For: Jun 30
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20260727/A5BYAG2C8Z22HZZU22Z82ZZZNTJAZ2U2Z28G
Filed on: July 27, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Imfinzi plus tarlatamab shows survival gains in lung cancer trial
- Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
- IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-sta
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
